Inhibikase Therapeutics, Inc. Income Statement
IKT|4 years of annual SEC 10-K data (FY2021-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
Inhibikase Therapeutics, Inc. reported $260,501 in revenue and $19M in net loss for FY2024. Revenue has declined at a 28.0% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $260.5K | $123.4K | $3.1M | $698.5K |
| SG&A Expense | $6.7M | $6.2M | $6.5M | $2.6M |
| R&D Expense | $13.6M | $12.0M | $11.4M | $893.8K |
| Operating Income | -$20.1M | -$18.1M | -$14.8M | -$2.8M |
| Interest Expense | $1.1M | $74.5K | -$19.9K | $29.4K |
| Net Income | -$19.0M | -$18.1M | -$14.8M | -$2.8M |
| EPS (Basic) | -$3.16 | -$4.28 | -$0.81 | - |
| EPS (Diluted) | -$3.16 | -$4.28 | -$0.81 | -$0.35 |
| Shares Outstanding | 6.2M | 4.2M | 25.2M | 10.1M |
| Operating Margin | -7712.0% | -14686.2% | -476.2% | -403.5% |
| Profit Margin | -7304.7% | -14625.9% | -476.9% | -407.7% |